BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, BCR::ABL1‐independent pathways and molecules or niche‐related factors may trigger growth and survival of leukemic stem cells (LSC) in CML and thereby contribute to drug resistance.26, 27, 28